Gender	Male
E-mail	robert.aiken@mssm.edu
Awards	2007 - 2008 Best Doctors in America
	2005 - 2006 Best Doctors in America
	2002 Top Doctors of Philadelphia Philadelphia Magazine
	2002 Best Doctors in the United States
	2000 Best Doctors in the United States
	1996 Top Doctors of Philadelphia Philadelphia Magazine
	1994 Top Doctors of Philadelphia Philadelphia Magazine
	1991 Top Doctors of Philadelphia Philadelphia Magazine

Robert D. Aiken, M.D., is Director of the Division of Neurological Oncology and Clinical Professor of Neurology in the Department of Neurology at Mount Sinai School of Medicine. A recognized leader in the field, Dr. Aiken works closely with the Departments of Neurosurgery and Radiation Oncology, and the Division of Hematology and Medical Oncology of the Department of Medicine to build a comprehensive program for treating patients with primary and metastatic tumors of the nervous system. He also has special interests in developmental therapeutics, neurological complications and systemic cancer, and the evaluation and management of cancer pain.

Dr. Aiken previously served as Clinical Professor of Neurology and was a medical neuro-oncologist at Thomas Jefferson University Hospital of Jefferson Medical College, in Philadelphia. While there, he co-founded the brain tumor program that has become one of the largest programs of its kind on the East Coast. He was recruited to Mount Sinai from the Institute of Neurology and Neurosurgery (INN) of Saint Luke's-Roosevelt Hospital Center and Beth Israel Medical Center where he was establishing a similar center.

He is a diplomat in Neurology of the American Board of Psychiatry and Neurology and has published widely on cancer related topics. He is a member of the American Academy of Neurology, American Society of Clinical Oncology (ASCO), Society for Neuro-Oncology, American Association for Cancer Research (AACR), and other professional societies.

Translational therapeutics: translating laboratory discoveries of malignant brain tumors into clinical trials.

Aiken RD. Neurologic complications of head and neck cancers [review]. Semin Oncol 2006 Jun; 33(3): 348-51.

Aiken RD. Treatment of brain tumors. N Engl J Med 2005 Jun 2; 352(22): 2350-3.

Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohen A, Gilbert M, Aiken R, Aiken RD, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002 May; 57(3): 231-9.

Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, Lafollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001 Jan; 84(2): 157-63.

Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G, Aiken RD. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001 Apr 15; 19(8): 2189-200.

Aiken RD, Wall M, Silberstein SD. Headache associated with abnormalities in intracranial structure or function: high cerebrospinal fluid pressure headache and brain tumor. In: Silberstein SD, Lipton RB, Dalessio DL, editors. Wolff's Headache and Other Head Pain. 7th ed. New York, Oxford University Press; 2001. pp393-416.

Aiken RD. Paraneoplastic Diseases. In: Mandel S, Willis J, editors. Handbook of Lower Extremity Neurology. 1st ed. Philadelphia, Churchill-Livingstone; 2000. pp113-17.

Vaccaro AR, Urban WC, Aiken RD. Delayed cortical blindness and recurrent quadriplegia after cervical trauma. J Spinal Disord 1998 Dec; 11(6): 535-9.